Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 7, pp. 1042-1055
Open Access | Times Cited: 165

Showing 26-50 of 165 citing articles:

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira, L. Puig, Tiago Torres
Drugs (2020) Vol. 80, Iss. 4, pp. 341-352
Closed Access | Times Cited: 137
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Thomas Bieber, Jacob P. Thyssen, Kristian Reich, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 476-485
Open Access | Times Cited: 125
JAK Inhibitors: Prospects in Connective Tissue Diseases
Hanxiao You, Dong Xu, Jiuliang Zhao, et al.
Clinical Reviews in Allergy & Immunology (2020) Vol. 59, Iss. 3, pp. 334-351
Closed Access | Times Cited: 105
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 5, pp. 693-707
Open Access | Times Cited: 102
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
William Damsky, Danielle Peterson, Julie Y. Ramseier, et al.
Journal of Allergy and Clinical Immunology (2020) Vol. 147, Iss. 3, pp. 814-826
Closed Access | Times Cited: 90
Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis
Daniel J. DeMizio, Laura Geraldino‐Pardilla
Rheumatology and Therapy (2019) Vol. 7, Iss. 1, pp. 19-33
Open Access | Times Cited: 88
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Yiming Luo, Madison Alexander, Massimo Gadina, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 911-925
Open Access | Times Cited: 88
Cardiovascular effects of approved drugs for rheumatoid arthritis
Fabiola Atzeni, Javier Rodríguez‐Carrio, Călin D. Popa, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 5, pp. 270-290
Closed Access | Times Cited: 79
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
Matthew J. Koster, Cynthia S. Crowson, Rachel Giblon, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 861-867
Open Access | Times Cited: 66
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Partha Biswas, Mohammad Mehedi Hasan, Dipta Dey, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 42, pp. 59570-59593
Open Access | Times Cited: 57
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 1, pp. 172-181
Open Access | Times Cited: 40
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Sarina B. Elmariah, Jeffrey S. Smith, Joseph F. Merola
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 427-431
Closed Access | Times Cited: 39
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 28
Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Lina Alhanshali, Michael G Buontempo, Kristen I. Lo Sicco, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 803-820
Open Access | Times Cited: 27
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 26
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 23
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Katie Bechman, Mark Yates, James Galloway
Pharmacological Research (2019) Vol. 147, pp. 104392-104392
Open Access | Times Cited: 74
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
The Lancet Rheumatology (2020) Vol. 2, Iss. 6, pp. e347-e357
Closed Access | Times Cited: 68
The role of interferon-γ in cardiovascular disease: an update
Ailin Elyasi, Iryna Voloshyna, Saba Ahmed, et al.
Inflammation Research (2020) Vol. 69, Iss. 10, pp. 975-988
Closed Access | Times Cited: 61
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
Puja Mehta, Coziana Ciurtin, Marie Scully, et al.
European Respiratory Journal (2020) Vol. 56, Iss. 3, pp. 2001919-2001919
Open Access | Times Cited: 59
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events
Fabiola Atzeni, Călin D. Popa, Valeria Nucera, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 3, pp. 233-244
Closed Access | Times Cited: 36
Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
Maurizio Benucci, Arianna Damiani, Maria Infantino, et al.
Pharmacological Research (2022) Vol. 183, pp. 106359-106359
Closed Access | Times Cited: 30
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
Robert Harrington, Patricia Harkins, Richard Conway
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6690-6690
Open Access | Times Cited: 21
Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry
Chi Chiu Mok, Ho So, Cheuk Wan Yim, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 358-365
Closed Access | Times Cited: 19

Scroll to top